Annals of Thoracic Medicine Official publication of the Saudi Thoracic Society, affiliated to King Saud University
 
Search Ahead of print Current Issue Archives Instructions Subscribe e-Alerts Login 
Home Email this article link Print this article Bookmark this page Decrease font size Default font size Increase font size

    Article Cited by others

ORIGINAL ARTICLE

Erlotinib in wild type epidermal growth factor receptor non-small cell lung cancer: A systematic review

Jazieh Abdul-Rahman, Al Sudairy Reem, Abu-Shraie Nada, Al Suwairi Wafaa, Ferwana Mazen, Murad M Hassan

Year : 2013| Volume: 8| Issue : 4 | Page no: 204-208

   This article has been cited by
 
1 Computational Insights into the Potential of Withaferin-A, Withanone and Caffeic Acid Phenethyl Ester for Treatment of Aberrant-EGFR Driven Lung Cancers
Vidhi Malik, Vipul Kumar, Sunil C. Kaul, Renu Wadhwa, Durai Sundar
Biomolecules. 2021; 11(2): 160
[Pubmed]  [Google Scholar] [DOI]
2 MicroRNA-16 Restores Sensitivity to Tyrosine Kinase Inhibitors and Outperforms MEK Inhibitors in KRAS-Mutated Non-Small Cell Lung Cancer
Francesca Fanini, Erika Bandini, Meropi Plousiou, Silvia Carloni, Petra Wise, Paolo Neviani, Mariam Murtadha, Flavia Foca, Francesco Fabbri, Ivan Vannini, Muller Fabbri
International Journal of Molecular Sciences. 2021; 22(24): 13357
[Pubmed]  [Google Scholar] [DOI]
3 Conformational Insight on WT- and Mutated-EGFR Receptor Activation and Inhibition by Epigallocatechin-3-Gallate: Over a Rational Basis for the Design of Selective Non-Small-Cell Lung Anticancer Agents
Cristina Minnelli, Emiliano Laudadio, Giovanna Mobbili, Roberta Galeazzi
International Journal of Molecular Sciences. 2020; 21(5): 1721
[Pubmed]  [Google Scholar] [DOI]
4 FGFR1 and FGFR4 oncogenicity depends on n-cadherin and their co-expression may predict FGFR-targeted therapy efficacy
Álvaro Quintanal-Villalonga, Irene Ferrer, Elizabeth Guruceaga, Cristina Cirauqui, Ángela Marrugal, Laura Ojeda, Santiago García, Jon Zugazagoitia, Sandra Muñoz-Galván, Fernando Lopez-Rios, Luis Montuenga, Silvestre Vicent, Sonia Molina-Pinelo, Amancio Carnero, Luis Paz-Ares
EBioMedicine. 2020; 53: 102683
[Pubmed]  [Google Scholar] [DOI]
5 Tyrosine Kinase Inhibitors in the Treatment of Choroidal Metastases from Non-Small-Cell Lung Cancer: A Case Report and Review of Literature
Akshay Gopinathan Nair, Haresh T. Asnani, Vinod C. Mehta, Siddharth V. Mehta, Rima S. Pathak, Amit H. Palkar, Indumati Gopinathan
Ocular Oncology and Pathology. 2017; 3(1): 28
[Pubmed]  [Google Scholar] [DOI]
6 24h-gene variation effect of combined bevacizumab/erlotinib in advanced non-squamous non-small cell lung cancer using exon array blood profiling
Florent Baty, Markus Joerger, Martin Früh, Dirk Klingbiel, Francesco Zappa, Martin Brutsche
Journal of Translational Medicine. 2017; 15(1)
[Pubmed]  [Google Scholar] [DOI]
7 Epidermal Growth Factor Receptor Inhibition in the Management of Squamous Cell Carcinoma of the Lung
Glenwood D. Goss, Johanna N. Spaans
The Oncologist. 2016; 21(2): 205
[Pubmed]  [Google Scholar] [DOI]
8 Hepatocyte growth factor reduces sensitivity to the epidermal growth factor receptor-tyrosine kinase inhibitor, gefitinib, in lung adenocarcinoma cells harboring wild-type EGFR
Hua Yang, Rong Wang, Shunli Peng, Longhua Chen, Qi Li, Wei Wang
Oncotarget. 2016; 7(13): 16273
[Pubmed]  [Google Scholar] [DOI]
9 Erlotinib as Second-Line Therapy for Patients with Advanced Non-Small-Cell Lung Cancer and Wild-Type EGFR Tumors
Sergio Vázquez, María José Villanueva, José Luis Fírvida, Begoña Campos, Martín Lázaro, Gerardo Huidobro, María del Carmen Areses, Natalia Fernández, Marta Covela , Joaquín Casal
Journal of Analytical Oncology. 2015; 4(3)
[Pubmed]  [Google Scholar] [DOI]
10 The HSP90 inhibitor ganetespib potentiates the antitumor activity of EGFR tyrosine kinase inhibition in mutant and wild-type non-small cell lung cancer
Donald L. Smith,Jaime Acquaviva,Manuel Sequeira,John-Paul Jimenez,Chaohua Zhang,Jim Sang,Richard C. Bates,David A. Proia
Targeted Oncology. 2015; 10(2): 235
[Pubmed]  [Google Scholar] [DOI]
11 S100A4 Is an Independent Prognostic Factor for Patients with Lung Cancer: A Meta-Analysis
Hao Bai,Jia-Lin Qian,Bao-Hui Han
Genetic Testing and Molecular Biomarkers. 2014; 18(5): 371
[Pubmed]  [Google Scholar] [DOI]

 

Read this article